BeyondSpring

Historical price data

BeyondSpring is a NASDAQ-listed biotech focused on developing plinabulin, a novel immunomodulating microtubule-binding agent, for oncology. Its primary objectives are securing approval for plinabulin to prevent chemotherapy-induced neutropenia (CIN) and demonstrating its efficacy as a combination therapy in non-small cell lung cancer (NSCLC). The company's strategy leverages a dual-mechanism platform to differentiate from standard care and targets high-value markets in the US and China. Despite a prior FDA Complete Response Letter for CIN, BeyondSpring continues to generate supportive clinical data, particularly from its Phase 3 DUBLIN-3 trial in NSCLC, to build a compelling case for global registration.

Centered on plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA) with a dual mechanism: activating GEF-H1 to promote immune response (dendritic cell/T-cell activation) and bone marrow protection (G-CSF release).

In CIN, plinabulin competes against entrenched G-CSF biologics and biosimilars (e.g., Neulasta). In NSCLC, it faces generic docetaxel and targeted therapies. Its success hinges on demonstrating clear clinical superiority (e.g., survival benefit, reduced side effects) to justify market penetration and premium pricing.